Skip to main content
Premium Trial:

Request an Annual Quote

Silence Inks Tech-Evaluation Deal with Miragen


Silence Therapeutics announced this week that it has signed a deal under which Miragen will evaluate its microRNA therapeutic candidates in combination with Silence's cationic lipid-based DBTC delivery technology.

Miragen will provide Silence with multiple specific miRNA sequences, which Silence will formulate with the DBTC technology. Miragen will then examine the compounds in vitro and in vivo, and have the option to select lead candidates for further development as therapeutics.

Additional terms of the arrangement were not disclosed.

“This is the third collaboration that we have recently signed to explore the use of Silence's delivery technologies for microRNAs,” Silence CEO Thomas Christely said in a statement. “Whilst we remain internally focused on the delivery of our siRNA therapies, we continue to broaden the potential value of our proprietary delivery systems by collaborating with partners.”

In October, Silence inked a DBTC-evaluation deal with Mirna Therapeutics (GSN 10/27/2011), although Mirna recently announced that it was going to use Marina Biotech's Smarticle lipids with numerous drug candidates (GSN 1/5/2012).

A month before that, Silence announced that InteRNA Technologies would examine Silence's core AtuPlex lipid delivery technology in combination with its own miRNA mimics (GSN 9/15/2011).

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.